Skip to main content
Danish real-world study anifrolumab use in 36 #SLE pts. SLEDAI-2K decreased from 8 (baseline) to 2 @ mos 3; @6 mos 52% h

Dr. John Cush RheumNow

3 months 2 weeks ago
Danish real-world study anifrolumab use in 36 #SLE pts. SLEDAI-2K decreased from 8 (baseline) to 2 @ mos 3; @6 mos 52% had SLEDAI-2K=0. 87% had PGA ≤0.5 w/ LLDAS, & 70% DORIS remission. Pred use declined by >50%. Herpes infx were most freq AE https://t.co/gNIAoXplMt https://t.co/D6xhQrY8ep
UK Our Future Health study of 1,563,155 finds affective Dz (depression, bipolar, anxiety) signific higher (p<0.001)in

Dr. John Cush RheumNow

3 months 2 weeks ago
UK Our Future Health study of 1,563,155 finds affective Dz (depression, bipolar, anxiety) signific higher (p<0.001)in autoimmune pts vs gen. pop. (29% vs 18%) - dx by PHQ-9, GAD-7. (OR 1.86), even after adjustments income and pain, etc. https://t.co/HoKBeAZxbS https://t.co/NtJhaf7WCo
ILD in RA – Dr. Jeffrey Sparks
In this https://t.co/4UQlqwujiR 2026 podcast, Dr. Jeffrey Sparks reviews the latest adv

Dr. John Cush RheumNow

3 months 2 weeks ago
ILD in RA – Dr. Jeffrey Sparks In this https://t.co/4UQlqwujiR 2026 podcast, Dr. Jeffrey Sparks reviews the latest advances shaping diagnosis and management of ILD in RA. 🎧 Listen here: https://t.co/U5cZVlgAka #Rheumatology #ILD #RNL2026 https://t.co/LidiS3Wj9d
Italian retrospective study 411 IIM pts classified cancer risk per IMACS criteria: 44% high-, 38% intermed- 18% standard

Dr. John Cush RheumNow

3 months 2 weeks ago
Italian retrospective study 411 IIM pts classified cancer risk per IMACS criteria: 44% high-, 38% intermed- 18% standard-risk. 9.2% had CA w/in 3yrs. Signif more in high-risk (OR 4.05). CA predictors: TIF1γ (OR  12.3), SAE1 (OR = 11.9) https://t.co/j4gA0g79bI https://t.co/Pt5nMs89bl
COMMON - Incidental Rotator Cuff Abnormalities on MRI

In this cross-sectional study of 602 Finnish adults undergoing b

Dr. John Cush RheumNow

3 months 2 weeks ago
COMMON - Incidental Rotator Cuff Abnormalities on MRI In this cross-sectional study of 602 Finnish adults undergoing bilateral shoulder magnetic resonance imaging (MRI) and clinical assessment, abnormalities were found in nearly everyone over age 40 years, regardless of whether https://t.co/2n58lglVP0
Advanced Practice Rheum: Methotrexate

In this session, we're going to review methotrexate. It is the most popular of d

Dr. John Cush RheumNow

3 months 2 weeks ago
Advanced Practice Rheum: Methotrexate In this session, we're going to review methotrexate. It is the most popular of disease-modifying drugs used in rheumatology. While it may be indicated for a few disorders, it's widely used in many inflammatory and autoimmune disorders. https://t.co/RKh3mQv7Hx
Asia-Pacific Lupus study of Mucocutaneous activity (MC-A) in 4102 SLE pts. 36% had MC-A (rash 1055; alopecia 731; m ulce

Dr. John Cush RheumNow

3 months 2 weeks ago
Asia-Pacific Lupus study of Mucocutaneous activity (MC-A) in 4102 SLE pts. 36% had MC-A (rash 1055; alopecia 731; m ulcers 352); 15% persistently. MC-A assoc w/ W, smoking, +serologies, vasculitis, myositis, serositis, nephritis, NP-SLE https://t.co/XeBc4DJon9 https://t.co/n2wAq2OIGt
Top Four and More (4.10.2026)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week - including his top four favorite subjects.
Hopkins Myositis study of 637 dermatomyositis pts - FLARES were assoc w/ DM Dz activity; manifest as rash (76%), motor w

Dr. John Cush RheumNow

3 months 2 weeks ago
Hopkins Myositis study of 637 dermatomyositis pts - FLARES were assoc w/ DM Dz activity; manifest as rash (76%), motor weakness (58%), Pulm (19%), arthritis (12%). O nly 2–5% of Flare pts had cancer Dx w/in 6–24-mos https://t.co/AKC9oIKAS7 https://t.co/26q8FfkUfl
Among neuro-ophthalmic complications of Immune Checkpoint Inhibitors, myasthenia gravis (often with concomitant myositis

Dr. John Cush RheumNow

3 months 2 weeks ago
Among neuro-ophthalmic complications of Immune Checkpoint Inhibitors, myasthenia gravis (often with concomitant myositis) is most common irAE, followed by optic neuropathy (often as optic neuritis) https://t.co/7pxqSKY3M1 https://t.co/bisbShFHIc
Predictors of Calcinosis Cutis in Systemic Sclerosis

Calcinosis cutis (CaC) is a common and disabling non-lethal manif

Dr. John Cush RheumNow

3 months 2 weeks ago
Predictors of Calcinosis Cutis in Systemic Sclerosis Calcinosis cutis (CaC) is a common and disabling non-lethal manifestation in systemic sclerosis (SSc). This study used SSc patients from the EUSTAR database to clinically characterize patients and identify risk factors for https://t.co/uXbcCa04Lv
VEXAS Syndrome - A Review

Beck et al has published a review of the VEXAS syndrome in The Lancet, focusing on the patho

Dr. John Cush RheumNow

3 months 2 weeks ago
VEXAS Syndrome - A Review Beck et al has published a review of the VEXAS syndrome in The Lancet, focusing on the pathogenesis, spectrum, and treatment strategies. https://t.co/Nik0TJm6Qu https://t.co/WS35PRnbBv
Itch is common in Scleroderma (SSc) and not related to Dz duration. Study of 2173 Pts (~20K itch assessments), 87 F; mea

Dr. John Cush RheumNow

3 months 3 weeks ago
Itch is common in Scleroderma (SSc) and not related to Dz duration. Study of 2173 Pts (~20K itch assessments), 87 F; mean age 55 yrs; 40% w/ diffuse SSc. Itch (moderate 4/10) seen in ~35% at all times https://t.co/QnT8d0xA5Z https://t.co/yEgB6ImDTi
The number of U.S. patients prescribed long-term opioid therapy declined from 2015 to 2023, but co-prescribing of opioids with gabapentinoids increased, prescription data showed.
×